LLY
Lilly(Eli) & Co
$1213.91+1.86%
Setup
Near pivot
Buy Zone
$1238-$1299.9
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
92
Recommendation
Watch
Hold
Quality acceptable but no fresh entry signal.
LLY chart
Loading chart…
Overall Quality92
RS Rating
77
relative strength
Fundamentals
92
Strong fund-Q
Volume Demand
82
+1% vs avg
Technical Setup
100
8/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Watch
Entry
$1238
Entry Zone
$1238-$1299.9
Stop / Risk
$1138.96
RS Rating
77
Volume confirmed
Yes
Targets
$1485.6 / $1547.5
Breakout · IBD Setup
6 ✓ 2 ✗
Entry $1238–$1299.9Stop $1138.96Target $1485.6 / $1547.5
Market regimeRange
Quality92
RS Rating77
Above 50-MA+15.07%
Above 200-MA+23.24%
VolumeConfirmed
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
92
MarketRange
SetupNear pivot
ConfidenceExperimental · not backtested
Fund-Q92 · Strong
StatusHold
Stock Data
52-Week Range624 – 1238
Price % Chg YTD12.96%
Price % Chg 4wk14.07%
50-Day Avg Vol3.3 Mil
P/E Ratio43.5
Market Cap$1.14T
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)169.45%
Sales % Chg (Qtr)55.55%
EPS Growth 5y27.59%
Sales Growth 5y21.58%
Annual ROE107.64%
Gross Margin82.83%
Operating Margin47.3%
Net Margin34.98%
Debt / Equity1.39
Setup levels
Current price
$1213.91
Pivot
$1238
Distance to buy
-1.9%
52-week range
623.77-1238.05
Trigger evidence
No active trigger evidence available.
Pattern levels: pivot 1238.0
Financial health checks
4/5
Return on equity above 15%
ROE 107.64%
Net margin above 10%
Net margin 34.98%
EPS growing quarter on quarter
EPS q/q 169.45%
Sales growing quarter on quarter
Sales q/q 55.55%
Debt to equity below 1.0
D/E 1.39
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE107.64%
vs sector +84.6%
Net margin34.98%
vs sector +15.7%
Gross margin82.83%
vs sector +11.2%
EPS growth q/q169.45%
vs sector +150.3%
Sales growth q/q55.55%
vs sector +34.4%
Debt / equity1.39
vs sector +0.67
Business quality
92
GradeStrong
EPS rating87
P/E43.5
Market cap$1.14T
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Pass
Volumen bestätigt
Pass
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
ADD_ON_PULLBACK2026-06-2500:18:20
Owned in the leaderboard portfolio, it's bouncing off the 21-day line and the 1,100 round number after a breakout, showing strong growth in GLP-1 drugs and a dynamic pipeline.
Signal history
Added to list
2026-06-28
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.